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Abstract 79 
Background: Complete and partial androgen insensitivity syndrome (CAIS, PAIS) are associated with 80 
an increased risk of gonadal germ cell cancer (GGCC). Recent guidelines recommend gonadectomy in 81 
women with CAIS in late adolescence. Nevertheless, many adult women prefer to retain their gonads.  82 
Aims: To explore attitudes towards gonadectomy in AIS in centres around the world, estimate the 83 
proportion of adults with retained gonads and/or who developed GGCC, and explore reasons for 84 
declining gonadectomy. 85 
Methods: Survey among health care professionals who use the International DSD Registry (I-DSD).  86 
Results: Data were provided from 22 centres in 16 countries on 166 women (CAIS) and 26 men (PAIS). 87 
In CAIS, gonadectomy is recommended in early adulthood in 67% of centres; 19/166 (11.4%) women 88 
refused gonadectomy. Out of 142 women who had gonadectomy; : or , evidence of germ cell neoplasm 89 
in situ (GCNIS), the precursor of GGCC, was reported in two (1.4%). Nine out of 26 men with PAIS 90 
(34.6%) had retained gonads; 11% of centres recommend routine gonadectomy in PAIS.  91 
Conclusion: Although development of GGCC seems rare, gonadectomy after puberty is broadly 92 
recommended in CAIS; in PAIS this is more variable. Overall, our data reflect the need for evidence-93 
based guidelines regarding prophylactic gonadectomy in AIS.  94 
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Introduction 95 
Androgen insensitivity syndrome (AIS) is caused by mutations in the Androgen Receptor (AR) gene, and 96 
results in a partial or complete resistance to androgens. The complete form of AIS (CAIS) occurs in less 97 
than 1 per 20.000 of 46,XY individuals, who then develop a female phenotype. In men and women with 98 
partial AIS (PAIS), the phenotype is highly variable, depending on the degree of residual androgen 99 
activity and other modifying factors [1]. Whereas a likely pathogenic variant in AR can be identified in 100 
85% of women who have CAIS, this is only the case in less than 30% of individuals who have clinical 101 
features suggestive of PAIS, suggesting that other mechanisms affect androgen signalling [2]. Providing 102 
care for individuals with AIS is best performed in a multidisciplinary setting and may be challenging [3–103 
6]. Points of uncertainty are whether gonadectomy should be performed and if so, at what age. 104 
Gonadectomy in AIS is commonly recommended because of the potential development of gonadal 105 
germ cell cancer (GGCC) [1]. This risk to develop GGCC has been related to the presence of TSPY (testis 106 
specific protein Y-encoded) in association with the suboptimal environment of the germ cell niche – 107 
due to the lack of androgen signaling - which negatively affects germ cell maturation [7–9]. Both the 108 
macro-environment (non-scrotal position of the testis) and micro-environment (in particular Sertoli 109 
cells) are affected. The invasive GGCC occurring in AIS, mainly seminoma, belong to the group of the 110 
Type II malignant germ cell tumours of the testis and dysgenetic gonad (see [10] for a review), and are 111 
for many years preceded by the presence of an in situ neoplastic lesion, termed now according to the 112 
most recent WHO classification, germ cell neoplasia in situ (GCNIS) [11]. An overview of reported cases 113 
in children and adults since 2000 is presented in Table 1; before that time, a molecular genetic 114 
diagnosis was most often not available and published series mostly reported on a mix of clinical 115 
diagnoses, including also many cases with gonadal dysgenesis, who are known to have a much higher 116 
risk [12]. Whereas the risk for GGCC has been estimated at less than 1% in childhood, uncertainty 117 
prevails concerning this risk in retained gonads after adolescence [13]. Therefore, it has been 118 
recommended to perform gonadectomy towards the end of puberty, allowing for spontaneous 119 
pubertal (breast) development, through the peripheral conversion of excess testosterone into 120 
estradiol [1,14,15]. However, evidence for this recommendation is weak as it is derived from a limited 121 
number of small case series. In the series of Deans et al. [16], fifteen percent of adult women who have 122 
CAIS declined gonadectomy for various reasons, posing challenges to the medical management as no 123 
reliable tumour markers or imaging techniques for the detection of early neoplastic lesions in 124 
abdominal gonads are currently available [17]. A study from our group in a relatively large sample 125 
(n=52) systematically explored the prevalence of GCNIS and even earlier histological changes. This 126 
study revealed a prevalence of pre-neoplastic changes, i.e. changes hypothesized to precede the 127 
development of GCNIS, of around 10% in young adult women (median age 17.5 years) with CAIS, with 128 
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no GCNIS or invasive lesions [18]. In countries where the diagnosis of CAIS is rarely made early and/or 129 
gonadectomy is not commonly performed due to socio-economic or cultural reasons, invasive or 130 
clinically manifest GGCC are seldom reported [19]. In line with this observation, it has been found that 131 
only few in situ lesions progress to invasiveness in individuals who have AIS [20]. A small number of 132 
studies report a positive effect of retained gonads on bone mineral density in women with CAIS, which 133 
cannot always be obtained by HRT [21,22]. For men and women with PAIS, recommendations for the 134 
management of gonads at risk have been proposed only recently, but the evidence remains weak and 135 
partly based on extrapolations from other conditions such as testosterone biosynthesis defects [9].  136 
This study aims to explore current attitudes towards gonadectomy in the context of AIS in DSD centres 137 
across the world, to estimate the prevalence of (pre)malignant germ cell changes in individuals who 138 
have genetically confirmed AIS and have undergone gonadectomy, as well as the occurrence of GCC in 139 
retained gonads. Physicians providing care for individuals who have AIS were recruited through the I-140 
DSD Registry (https://www.i-dsd.org) [23]. 141 
  142 
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Methodology 143 
Recruitment 144 
An international survey was performed among health care professionals working in DSD centres 145 
around the world between 2015 and 2017. Contact details of clinicians were retrieved through the I-146 
DSD Registry. A total of 41 centres (28 European and 13 non-European) were contacted by e-mail, with 147 
three reminders sent to centres that did not reply. The questionnaires were attached to these e-mails 148 
and centres were asked to return the completed forms electronically. 149 
Questionnaire  150 
The first section of the questionnaire concerned adult women (≥16 years) who have CAIS and was 151 
divided in two parts. The first part asked about the number of individuals with CAIS known to the 152 
centre and general attitudes of the centre towards gonadectomy (Table 1). Part two explored 153 
individuals who had not undergone gonadectomy in more detail, focussing on reasons for declining 154 
gonadectomy and if there had ever been any suspicion of tumour development (Table 2).  155 
The second section of the survey explored adult men (≥16 years) who have PAIS and followed the same 156 
structure as the previous section (Table 3).  157 
Statistics  158 
Statistical analysis was performed using IBM SPSS software package (version 25). A p-value of less than 159 
0.05 was considered significant. To test whether centres that do not recommend gonadectomy on a 160 
routine basis had more individuals with retained gonads than other centres, a Pearson Chi-Square test 161 
and Fisher’s Exact test were used for CAIS and PAIS respectively. 162 
  163 
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Results 164 
General 165 
Twenty-two out of 41 contacted centres (53.7%) replied to the survey. Of these, there were eighteen 166 
European and four non-European centres (18.2%) (USA, Sudan, Israel and Turkey). However, not all 167 
questionnaires were fully completed, mostly because patient data were unavailable after transition to 168 
an adult department. This led to missing data for 10 centres (45.5%). A total of 160 emails were sent 169 
to the centre leads of all centres combined (including reminders). In total, data were collected on 175 170 
women with CAIS and 26 men with PAIS. 171 
 172 
Complete androgen insensitivity syndrome 173 
General attitudes towards gonadectomy (Table 2).  174 
Of 166 women, 24 (14.5%) had retained gonads at the time of the survey. Gonadectomy was 175 
performed on a routine basis during childhood in four out of the 21 centres (19%), whereas it was 176 
routinely proposed after puberty in 12 of 18 centres (67%) that replied to this question (Fig 1A, B). Six 177 
centres reported not to propose gonadectomy on a routine basis at any age but to perform the 178 
procedure according to patients’ preferences. In these centres, nine out of forty-four women (20.5%) 179 
had retained gonads at the time of the survey as compared to fifteen of the 122 women (12.3%) at all 180 
other centres (p=0.187). Centre-specific gonadectomy rates varied from 0% to 100%. Two of 142 181 
women (1.4%) who had gonadectomy were diagnosed with GCNIS, according to the clinicians’ 182 
information, no invasive GGCC were reported. No data are available about the age of these women at 183 
the time of the procedure or about the medical indication (e.g. presence of complaints or symptoms, 184 
tumour suspicion on imaging studies) for gonadectomy. 185 
 186 
Women older than 16 years with CAIS and who have retained gonads (Table 3) 187 
Twenty-four women were reported to have retained gonads, of which 50% had abdominal and 25% 188 
had inguinal gonads; the gonadal location was unknown in the remaining 25%. Median age of these 189 
women was 20 years (range: 16-48 years). Out of these 24 women, 19 (79.2%) preferred not to have 190 
gonadectomy, one had never been advised to have gonadectomy and for the four remaining cases, no 191 
further information was available. For 13 out of the 19 women who declined gonadectomy, a specific 192 
reason was reported. Multiple reasons were given in eight women (61.5%). Concerns about the 193 
procedure was the most frequently reported reason (8/13 women), followed by inconvenience to plan 194 
surgery when it was proposed (6/13 women), not wanting hormone replacement therapy (5/13 195 
women) and not having come to terms with the diagnosis yet (4/13). In addition, clinicians reported 196 
that two of those thirteen women were unaware of or did not understand the cancer risk. 197 
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 198 
Men who have PAIS (Table 4) 199 
Eighteen out of 22 centres provided information on whether they recommend routine gonadectomy 200 
to their male patients who have PAIS. One (5.6%) centre reported to routinely perform gonadectomy 201 
during childhood in boys who have PAIS; in four other centres, the decision depends on the gonadal 202 
location. Two centres perform gonadectomy as a standard procedure during adolescence/adulthood, 203 
whereas in four centres (22.2%), the decision was made on a case by case basis, taking into account 204 
gonadal function and location of the gonads (Fig 1C,D). Five out of nine men (55.6%) followed in centres 205 
that do not perform gonadectomy on a routine basis at any age had retained at least one gonad 206 
compared to four out of the seventeen men (23.5%) of the remaining centres (p=0.194). Information 207 
was available on twenty-six men with PAIS older than 16 years. Only nine men (34.6%) were reported 208 
to have at least one retained gonad at the time of the survey. In 11 men, this information was 209 
unavailable. Of the nine men who had at least one retained gonad, seven had scrotal testes, one had 210 
bilateral inguinal testes and one had an abdominal testis. The latter was reported to have undergone 211 
unilateral gonadectomy at the age of 55 years for suspicion of GGCC. However, no malignancy was 212 
found, the final diagnosis being Leydig cell hyperplasia.   213 
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Discussion 214 
This study tries to capture attitudes towards gonadectomy for AIS in DSD centres around the world. 215 
Through the I-DSD Registry, information was obtained from 22 centres, jointly following a reasonably 216 
large cohort of individuals with AIS, mainly women with CAIS. In addition, we have tried to collect 217 
information on the natural evolution of retained gonads in this condition, with respect to development 218 
of a GGCC. Eventually underlying motivating factors in affected individuals for declining gonadectomy 219 
were also explored. 220 
The response rate of our survey was 53.7%, which we consider reasonably high for a time-consuming 221 
survey. Since only four of the 13 (30.8%) approached centres from outside Europe participated, our 222 
study mainly reflects practices within European centres. Differences in timing of gonadectomy were 223 
seen on an international level, as well as within countries, suggesting that recently issued 224 
recommendations to postpone gonadectomy until adulthood are not generally implemented [1,15]. 225 
Insufficiently convincing evidence due to small sample sizes as well as sociocultural reasons may partly 226 
account for this variation in practice [14]. 227 
Nevertheless, from our survey it is clear that currently, most clinicians from participating centres prefer 228 
to postpone gonadectomy until after puberty so that secondary sex characteristics can develop 229 
optimally [24,25]. Eleven percent of the women with CAIS in our study had declined a gonadectomy 230 
and the main reasons for declining were concerns about the procedure, inconvenience of planning 231 
surgery, not wanting HRT and not having adjusted to the diagnosis. These results are in line with the 232 
study of Deans et al. [16]. 233 
Recent data and a meta-analysis of historical series suggest a risk for in situ lesions and preneoplastic 234 
changes of the germ cells of 10-15% in retained gonads, mainly in women with CAIS. However, it is 235 
unclear to what extent these lesions will show invasive progression later in life [16,18–20,26–28]. To 236 
our best knowledge, no invasive GGCC had occurred so far in the 166 adult women included in our 237 
survey. However, in two out of 142 women (1.4%) who had gonadectomy, a histological diagnosis of 238 
GCNIS was established according to the case files. This number has to be interpreted with caution as 239 
detailed histopathological findings of the gonadal tissue were only provided for eight women including 240 
the two who had GCNIS, but it is in line with recently reported data [18,19]. Although the risk of GGCC 241 
may be small, monitoring abdominal gonads for early neoplastic changes in those who decline 242 
gonadectomy is challenging. Relocation of the gonads to a more superficial region may be an 243 
alternative [29]. To date, little evidence-based data exist that guides clinicians in when to propose a 244 
gonadectomy in AIS. Based on the findings of this and our previous studies, we propose the clinical 245 
algorithm presented in figure 2 and 3. In addition, when discussing the pros and cons of gonadectomy, 246 
the agency of an individual should be taken into account. However, this is currently poorly identified. 247 
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Developing a validated questionnaire or checklist can help clinicians assess their patient’s 248 
understanding of the complex medical information they receive and their correct appraisal of the 249 
consequences of a decision in favour or against gonadectomy [30,31]. Important questions and factors 250 
that should be included in this questionnaire are represented in table 5. 251 
A low number (34.6%) of men who have PAIS had at least one retained gonad, even in centres that do 252 
not perform gonadectomy on a routine basis at any age (55.6% vs. 23.5%). Given the functional 253 
importance of the testes and easy accessibility in scrotal position (for some after orchidopexy) for 254 
follow-up by self-examination and ultrasound, this finding is surprising. It is possible that the testes 255 
were located too high for successful orchidopexy in some men, which could (partially) explain the high 256 
gonadectomy rate. Although a higher GGCC risk was initially reported in PAIS as compared to CAIS 257 
[7,8], a more recent study did not confirm such findings [18].  258 
Increasingly it is felt that the testes can be safely preserved in most men with PAIS, especially in the 259 
case of a scrotal position, under the condition that a strict surveillance protocol is insured. This 260 
surveillance should consist of regular follow-up by self-examination and ultrasound, as well as a testis 261 
biopsy in early adulthood which is then evaluated for the presence of GCNIS in an experienced 262 
pathology service, as proposed by van der Zwan et al. [9].  263 
 264 
Limitations of this study are the small number of participating centres from outside Europe, and the 265 
sometimes only partially completed questionnaires. All information, including histology, was as 266 
reported by clinicians but was not confirmed by independent analysis. In addition, we had no access 267 
to detailed patient data, e.g. regarding hormone levels, type of AR mutation or residual androgen 268 
activity. The strength of this study is the inclusion of a large cohort of adult women with CAIS, from 269 
whom data were available.  270 
 271 
In conclusion, practices towards gonadectomy in AIS vary around the world and within countries. In 272 
CAIS, the majority of centres tend to routinely propose gonadectomy to affected women at the end of 273 
puberty, but an estimated 11% of women further postpone this procedure. Main reasons are 274 
inconvenient timing, not having come to terms with the diagnosis and concerns about the procedure 275 
and about consequences of HRT. In men with PAIS, patient factors such as gonadal function and 276 
location seem to influence the decision for gonadectomy. However, the majority of men with PAIS 277 
were reported to have undergone bilateral gonadectomy. No invasive GGCC were reported in 166 278 
women with CAIS. Of the 142 women with CAIS who had gonadectomy, GCNIS was reported in two, 279 
whereas no (pre)malignancies were reported in adult men with PAIS. Taken together, our data 280 
highlight the lack of standardization concerning gonadectomy in AIS, and suggest a low incidence of 281 
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invasive GGCC in AIS during adulthood. Therefore, individualised decision-making, taking also into 282 
account patient preferences and agency, rather than chronological age, seems appropriate.  283 
 284 
Acknowledgements: The authors would like to thank all the participating centres for providing all the 285 
information needed for this study. Contact details from the participating centres were retrieved 286 
through the I-DSD Registry (https://www.i-dsd.org/). The authors would like to thank Jillian Bryce for 287 
administrative support. The I-DSD Registry was supported by Medical Research Council partnership 288 
award G1100236 and was initially developed under a project grant from the Seventh European Union 289 
Framework Program (201444) and a project grant from the Research Unit of the European Society for 290 
Pediatric Endocrinology. Martine Cools is supported by a Senior Clinical Investigator grant from the 291 
Flanders Research Foundation.  292 
References 293 
1  Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J: Androgen 294 
insensitivity syndrome. Lancet 2012;380:1419–1428.  295 
2  Hornig NC, Ukat M, Schweikert HU, Hiort O, Werner R, Drop SLS, et al.: Identification of an AR 296 
Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity. J 297 
Clin Endocrinol Metab 2016;101:4468–4477.  298 
3  Beale JM, Creighton SM: Long-term health issues related to disorders or differences in sex 299 
development/intersex. Maturitas 2016;94:143–148.  300 
4  Hiort O, Birnbaum W, Marshall L, Wünsch L, Werner R, Schröder T, et al.: Management of 301 
disorders of sex development. Nat Rev Endocrinol 2014;10:520–529.  302 
5  Hughes IA: Consensus statement on management of intersex disorders. Arch Dis Child 303 
2005;91:554–563.  304 
6  Cools M, Nordenström A, Robeva R, Hall J, Westerveld P, Flück C, et al.: Caring for individuals 305 
with a difference of sex development (DSD): a Consensus Statement. Nat Rev Endocrinol 306 
2018;14:415–429.  307 
7  Cools M, van Aerde K, Kersemaekers A-M, Boter M, Drop SLSS, Wolffenbuttel KP, et al.: 308 
Morphological and immunohistochemical differences between gonadal maturation delay and 309 
early germ cell neoplasia in patients with undervirilization syndromes. J Clin Endocrinol Metab 310 
2005;90:5295–303.  311 
8  Cools M, Drop SLSS, Wolffenbuttel KP, Oosterhuis JW, Looijenga LHJJ: Germ Cell Tumors in the 312 
Intersex Gonad: Old Paths, New Directions, Moving Frontiers. Endocr Rev 2006;27:468–484.  313 
9  van der Zwan YG, Biermann K, Wolffenbuttel KP, Cools M, Looijenga LHJ: Gonadal 314 
Maldevelopment as Risk Factor for Germ Cell Cancer: Towards a Clinical Decision Model. Eur 315 
Urol 2015;67:692–701.  316 
13 
 
10  Oosterhuis JW, Looijenga LHJ: Testicular germ-cell tumours in a broader perspective. Nat Rev 317 
Cancer 2005;5:210–222.  318 
11  Idrees MT, Ulbright TM, Oliva E, Young RH, Montironi R, Egevad L, et al.: The World Health 319 
Organization 2016 classification of testicular non-germ cell tumours: a review and update 320 
from the International Society of Urological Pathology Testis Consultation Panel. 321 
Histopathology 2017;70:513–521.  322 
12  Cools M, Wolffenbuttel KP, Drop SLS, Oosterhuis JW, Looijenga LHJ: Gonadal development 323 
and tumor formation at the crossroads of male and female sex determination. Sex Dev 324 
2011;5:167–80.  325 
13  Cools M, Looijenga L: Update on the Pathophysiology and Risk Factors for the Development of 326 
Malignant Testicular Germ Cell Tumors in Complete Androgen Insensitivity Syndrome. Sex Dev 327 
2017; DOI: 10.1159/000477921 328 
14  Bertelloni S: Gonadal Surgery in Complete Androgen Insensitivity Syndrome: A Debate. Sex 329 
Dev 2017; DOI: 10.1159/000475907 330 
15  Lee PA, Nordenström A, Houk CP, Ahmed SF, Auchus R, Baratz A, et al.: Global Disorders of 331 
Sex Development Update since 2006: Perceptions, Approach and Care. Horm Res Paediatr 332 
2016;85:158–180.  333 
16  Deans R, Creighton SM, Liao L-M, Conway GS: Timing of gonadectomy in adult women with 334 
complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence. 335 
Clin Endocrinol (Oxf) 2012;76:894–898.  336 
17  Cools M, Looijenga LHJ, Wolffenbuttel KP, T’Sjoen G: Managing the Risk of Germ Cell 337 
Tumourigenesis in Disorders of Sex Development Patients; in : Endocrine development. 2014, 338 
pp 185–196. 339 
18  Cools M, Wolffenbuttel KP, Hersmus R, Mendonca BB, Kaprová J, Drop SLS, et al.: Malignant 340 
testicular germ cell tumors in postpubertal individuals with androgen insensitivity: 341 
prevalence, pathology and relevance of single nucleotide polymorphism-based susceptibility 342 
profiling. Hum Reprod 2017;32:2561–2573.  343 
19  Chaudhry S, Tadokoro-Cuccaro R, Hannema SE, Acerini CL, Hughes IA: Frequency of gonadal 344 
tumours in complete androgen insensitivity syndrome (CAIS): A retrospective case-series 345 
analysis. J Pediatr Urol 2017;13:498.e1-498.e6.  346 
20  Kaprova-Pleskacova J, Stoop H, Brüggenwirth H, Cools M, Wolffenbuttel KP, Drop SLS, et al.: 347 
Complete androgen insensitivity syndrome: factors influencing gonadal histology including 348 
germ cell pathology. Mod Pathol 2014;27:721–30.  349 
21  Bertelloni S, Meriggiola MC, Dati E, Balsamo A, Baroncelli GI: Bone Mineral Density in Women 350 
Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads. 351 
14 
 
Sex Dev 2017;11:182–189.  352 
22  Döhnert U, Wünsch L, Hiort O: Gonadectomy in Complete Androgen Insensitivity Syndrome: 353 
Why and When? Sex Dev 2017;11:171–174.  354 
23  Ahmed SF, Rodie M, Jiang J, Sinnott RO: The European Disorder of Sex Development Registry: 355 
A Virtual Research Environment. Sex Dev 2010;4:192–198.  356 
24  Kathrins M, Kolon TF: Malignancy in disorders of sex development. Transl Androl Urol 357 
2016;5:794–798.  358 
25  Patel V, Casey RK, Gomez-Lobo V: Timing of Gonadectomy in Patients with Complete 359 
Androgen Insensitivity Syndrome–Current Recommendations and Future Directions. J Pediatr 360 
Adolesc Gynecol 2016;29:320–325.  361 
26  Nakhal R.S., Hall-Craggs M., Freeman A., Kirkham A., Conway G.S., Arora R., et al.: Evaluation 362 
of retained testes in adolescent girls and women with complete androgen insensitivity 363 
syndrome. Radiology 2013;268:153–160.  364 
27  Cheikhelard A, Morel Y, Thibaud E, Lortat-Jacob S, Jaubert F, Polak M, et al.: Long-Term 365 
Followup and Comparison Between Genotype and Phenotype in 29 Cases of Complete 366 
Androgen Insensitivity Syndrome. J Urol 2008;180:1496–1501.  367 
28  Audi L, Fernández-Cancio M, Carrascosa A, Andaluz P, Torán N, Piró C, et al.: Novel (60%) and 368 
recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY 369 
disorder of sex development. J Clin Endocrinol Metab 2010;95:1876–1888.  370 
29  Wolffenbuttel KP, Hersmus R, Stoop H, Biermann K, Hoebeke P, Cools M, et al.: Gonadal 371 
dysgenesis in disorders of sex development: Diagnosis and surgical management. J Pediatr 372 
Urol 2016;12:411–416.  373 
30  Hullmann SE, Chalmers LJ, Wisniewski AB: Transition from pediatric to adult care for 374 
adolescents and young adults with a disorder of sex development. J Pediatr Adolesc Gynecol 375 
2012;25:155–7.  376 
31  McCracken KA, Fallat ME: Transition from pediatric to adult surgery care for patients with 377 
disorders of sexual development. Semin Pediatr Surg 2015;24:88–92.  378 
32  Ahmed SF, Cheng A, Dovey L, Hawkins JR, Martin H, Rowland J, et al.: Phenotypic features, 379 
androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen 380 
insensitivity syndrome. J Clin Endocrinol Metab 2000;85:658–65.  381 
33  Hannema SE, Scott IS, Rajpert-De Meyts E, Skakkebæk NE, Coleman N, Hughes IA: Testicular 382 
development in the complete androgen insensitivity syndrome. J Pathol 2006;208:518–527.  383 
  384 
15 
 
Legends:  385 
Figure 1: Preferences of centres regarding gonadectomy. A: Preferences of centres regarding 386 
gonadectomy in women with CAIS before puberty; B: Preferences of centres regarding gonadectomy 387 
in women with CAIS after puberty; C: Preferences of centres regarding gonadectomy in men with PAIS 388 
before puberty; D: Preferences of centres regarding gonadectomy in men with PAIS after puberty. 389 
Proportion of centres that recommend routine gonadectomy (light grey), solely on indication (dark 390 
grey), based on gonadal location (horizontal stripes), based on gonadal function (vertical stripes). 391 
Figure 2. Clinical algorithm for considering gonadectomy in CAIS. GCNIS: germ cell neoplasm in situ, 392 
GGCC: gonadal germ cell cancer; HRT: hormone replacement therapy; US: ultrasound; MRI: magnetic 393 
resonance imaging; alphaFP: alpha fetoprotein; betaHCG: beta human chorionic gonadotropin; miR: 394 
novel serum microRNA. 395 
Figure 3. Clinical algorithm for considering gonadectomy in PAIS. GCNIS: germ cell neoplasm in situ, 396 
GGCC: gonadal germ cell cancer; HRT: hormone replacement therapy; US: ultrasound; MRI: magnetic 397 
resonance imaging; alphaFP: alpha fetoprotein; betaHCG: beta human chorionic gonadotropin; miR: 398 
novel serum microRNA; DHT: dihydrotestosterone. 399 
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Table 1. Overview of reported germ cell cancers in androgen insensitivity syndrome since 2000. 401 
Author Year Reported gonadal tumors 
Ahmed [32] 2000 CAIS: 
- GCNIS/GGCC: 0/65 
PAIS: 
- GCNIS/GGCC: 0/56 
Hannema [33] 2006 CAIS (mostly prepubertal cases): 
- GCNIS: 2/44 (4.5%), age: 17 and 53 years 
- GGCC: 0/44 
Cheikhelard [27] 2008 CAIS: 
- GCNIS: 1/29 (3.4%), age: 14 years 
Audi [28] 2010 CAIS/PAIS: 
- GCNIS/GGCC: 0/13 (CAIS & PAIS) 
Nakhal [26] 2013 CAIS (>16 years old): 
- GCNIS: 3/25 (12%), age: 19, 20 and 38 years 
Chaudhry [19] 2017 CAIS: 
- GCNIS: 7/133 (5.3%), age: 1.6, 2.8, 16, 17, 17, 20 and 53 years 
- GGCC: 2/133 (1.5%), age: 30 and 68 years 
Cools [18] 2017 CAIS: 
- Pre-GCNIS: 6/42 (14.3%), age: 14, 15, 15, 18, 21 and 22 years 
- GCNIS/GGCC: 0/42 
PAIS: 
- Pre-GCNIS: 1/10 (10%), age: 15 years 
- GCNIS/GGCC: 0/10 
CAIS: complete androgen insensitivity syndrome; PAIS: partial androgen insensitivity syndrome; GGCC: gonadal germ cell 402 
cancer; GCNIS: germ cell neoplasm in situ; Age: age of individual(s) with reported (pre-)GCNIS/GGCC.  403 
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Table 2. Women with CAIS (≥16 years old): approach of centres towards gonadectomy and proportion 404 
of women with retained gonads. 405 
Centre Number of patients Gonadectomy in 
childhood 
Gonadectomy in 
adolescence or 
adulthood 
No gonadectomy 
1 25 No  Yes  2/25 (8.0%) 
2 16 No NA 3/16 (18.8%) 
3 12 No  No  1/12 (8.3%) 
4 0 No  No  0/0  
5 3 No  Yes  3/3 (100%) 
6 5 Yes  Yes  0/5 (0%) 
7 5 Yes  Yes  1/5 (20%) 
8 3 No  Yes  1/3 (33.3%) 
9 9 No  No  1/9 (11.1%) 
10 11 No  Yes  1/11 (9.1%) 
11 1 No  No  1/1 (100%) 
12 5 No  Yes  0/5 (0%) 
13 NA No  No NA 
14 2 NA NA 1/2 (50%) 
15 2 Yes  NA 1/2 (50%) 
16 17 No  Yes  0/17 (0%) 
17 0 No  Yes  0/0  
18 3 No  Yes  0/3 (0%) 
19 1 Yes  Yes  1/1 (100%)+ 
20 22 No No 6/22 (27.3%) 
21 0 No NA 0/0 
22 24 No Yes 1/24 (4.2%) 
Total 166 4/21 (19%) 12/18 (66.7%) 24/166 (14.5%) 
NA: Not available/missing; Number of patients: number of patients with CAIS, ≥16 years of age followed per centre; +:Died of 406 
an unrelated condition before the (recommended) gonadectomy procedure had been performed  407 
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Table 3. Summary of women who have CAIS (≥16 years old) with retained gonads: descriptive statistics, 408 
gonadal location and reasons for declining gonadectomy. 409 
Descriptive statistics 
Number of cases N = 24 
Mean age ± SD 24.2 ± 8.12 
Declined gonadectomy 19/24 (79.2%) 
Gonadectomy had not been proposed 1/24 (4.2%) 
Missing/lost to follow-up 4/24 (16.7%) 
Gonadal location 
Missing 12/24 
Abdominal 6/12 (50%) 
Inguinal 3/12 (25%) 
Unknown 3/12 (25%) 
Reasons for declining 
Not specified 6/19 (31.6%) 
Concerns about the procedure 8/13 (61.5%) 
Inconvenient to plan surgery 6/13 (46.2%) 
Concerns about HRT 5/13 (38.5%) 
Had not come to terms with diagnosis yet 4/13 (30.8%) 
Unaware of malignancy risk or doesn’t understand the malignancy risk 2/13 (15.4%) 
Not specified: No specific reason was given as to why gonadectomy was refused, including wanting to wait to make the 410 
decision; SD: standard deviation; HRT: hormone replacement therapy.  411 
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Table 4. Men with PAIS: approach of centres towards gonadectomy, proportion of men with retained 412 
gonads and gonadal location of retained gonads 413 
Centre Gonadectomy: 
childhood 
Gonadectomy: 
Adolescence or 
Adulthood 
#no gonadectomy / 
#total 
Location gonads 
1 Yes* Yes*  NA  
2 No  No  0/0  
3 No  No  2/2 Both scrotal 
4 No  No  1/1 Scrotal  
5 Yes  No 0/0  
6 Yes*  No  1/2 Scrotal 
7 NA NA 0/0  
8 No  Case specific 0/0  
9 No  No  1/1 Abdominal 
10 No Yes  0/12  
11 No  No  0/0  
12 No  Yes# NA/10  
13 NA NA NA  
14 NA NA NA  
15 Yes*  Yes  1/1 Inguinal 
16 No  No  1/1 Scrotal 
17 No  No  NA/1  
18 No  Yes# 2/2 Both Scrotal 
19 NA NA NA  
20 No No 0/4  
21 Yes* Yes* 0/0  
22 No No 0/0  
Total Yes: 1/18 (5.6%) 
Yes*: 4/18 (22.2%) 
Yes: 2/18 (11.1%) 
Yes*: 2/18 (11.1%) 
Yes#: 2/18 (11.1%) 
9/26 (34.6%) 7 scrotal, 1 inguinal, 
1 abdominal 
#no gonadectomy/#total: number of men with at least one retained gonads / total number of men with PAIS followed per 414 
center. NA: Not available/missing; Number of patients: number of men who have PAIS (≥16 years of age) followed per centre; 415 
Yes*: choice depends on location of gonads; Yes#: choice depends on the function of gonads. 416 
  417 
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Table 5. Assessing agency and readiness for gonadectomy in AIS (modified from [30,31]). 418 
Key Questions 
Does the individual know his/her health history? 
Does the individual understand the diagnosis of AIS? 
Can the individual ask relevant and insightful questions to the involved health care providers regarding AIS? 
Can the individual weigh the risks and benefits specific of his/her own situation, regarding (postponing) gonadectomy?  
Is the patient capable of finding useful information on AIS and gonadectomy? (internet, support groups,…) 
Is there sufficient social support to make important health-related decisions? 
Has the individual come to terms with the diagnosis? 
Important factors to be weighed in  
Independence and willingness to make and attend own appointments with health care providers 
Willingness to take hormone replacement therapy 
Ability to perform gonadal exams and (if applicable) self-exams 
The current social, educational and / or professional context of the individual 
 419 
